

Programme

EASL School 2027

INFECTIONS IN ADVANCED CHRONIC LIVER DISEASES

Zagreb, 04 – 05 June 2027

Friday 04 June 2027

08:30-09:00	Registration
09:00-09:15	Introduction of format, program and aims of the EASL School
09:15 – 09:40	Infections in cirrhosis: immune dysfunction and clinical implications <i>Iva Košuta, Tomisla Kelava</i>
09:40– 10:05	SBP in 2027 - A changing disease - Do our guidelines need to catch up? <i>Marina Berenguer</i>
10:05 – 10:30	Lung - Liver interplay: Why respiratory infections hit hard in cirrhosis? <i>Carmen Vinaixa</i>
10:30 – 10:45	Discussion
10:45 – 11:15	Coffee break
11:15 – 11:40	From Petri dish to bedside: Aligning microbiological results with hepatology practice <i>Iva Butić</i>
11:40 – 12:05	The most common mistakes in antibiotic use in advanced chronic liver disease <i>Neven Papić</i>
12:05 – 12:30	Saving the failing liver: Modern management and game-changers in ACLF care. <i>Marina Berenguer</i>
12:30 – 12:45	Discussion
12:45 – 13:45	Lunch
13:45 – 14:15	State of the Art Lecture: Antimicrobial stewardship challenges in cirrhotic patients <i>Arjana Tambić Andrašević</i>
14:15 – 15:00	Panel discussion: MDR challenge - time to change antimicrobial therapy recommendations? <i>Marina Berenguer, Carmen Vinaixa, Iva Butić, Arjana Tambić Andrašević, Iva Košuta, Anna Mrzljak, Neven Papić</i>
15:00 – 15:30	Coffee break
15:30 – 18:00	Case-based problem solving (workshops) – group 1-5

18:30

Zagreb Highlights & Bites (*Social Programme*)

Saturday 05 June 2027.

09:00-09:15

Wrap up from yesterday

09:15 – 11:00

Group work presentations

11:00– 11:30

Coffee break

11:30 – 12:30

Pros & cons

Is my patient with an infection transplantable?

Carmen Vinaixa (Pro), Vibor Šeša (Con), Iva Košuta (Moderator)

12:30 – 12:50

Infections after liver transplantation – tailoring immunosuppression, biomarker-guided decisions and L/K-specific strategies

Anna Mrzljak

12:50 – 13:15

Course wrap-up, post-quiz review, student evaluation and feedback, conclusions, and farewell

13:15 – 14:00

Farewell lunch

WORKSHOPS

Group	Description (goals)
TIPSITIS Group 1	Participants will define “endotipsitis/TIPS infection,” recognize typical clinical scenarios and outline a diagnostic approach. They will propose a practical management algorithm covering empiric and targeted antimicrobial therapy, duration and suppressive therapy, indications for TIPS revision/removal or transplant referral, and key evidence gaps to inform an updated local guideline.
Fungal Infections in Cirrhosis and Beyond Group 2	Participants will discuss fungal risk stratification beyond the ICU setting, limitations of classical biomarkers (galactomannan, B-D glucan) in cirrhosis, personalized antifungal prophylaxis strategies post LT. They will critically identify limitations of current guidance and propose a pragmatic, locally adaptable “updated guideline” with clear decision points.
Managing Multi-Source Complex Infection in a Transplant Candidate Group 3	Participants will present an integrated, multidisciplinary management plan for a transplant-listed cirrhotic patient with sepsis complicated by spondylodiscitis, endocarditis, and worsening immune thrombocytopenia. They will justify diagnostic priorities (source control, imaging, microbiology), antimicrobial strategy (empiric → targeted, duration, toxicity/PK in cirrhosis), and coordinated decision-making with hepatology, ID, cardiology, spine surgery, hematology, and transplant teams, proposing a pragmatic pathway for similar high-risk cases.
Vaccination in Liver Transplant Candidates Group 4	Participants will design an evidence-informed vaccination plan for a patient on the transplant waiting list. They will weigh pros/cons and timing (urgency of transplant, immunogenicity in cirrhosis, live vs inactivated vaccines, dose schedules/boosters), address special situations (prior immunity/serology, recent biologics/steroids, household vaccination), and propose a pragmatic checklist-based pathway to improve vaccine uptake.
CMV Under Pressure: Refractory Disease, Drug Toxicity, and Immunosuppression Balance Group 5	Participants will present a management algorithm for a complex CMV case, integrating diagnostics and treatment strategy (valganciclovir vs IV ganciclovir, when to suspect resistance, and when/how to order genotypic resistance testing). They will propose an escalation plan for refractory/resistant CMV (for prophylaxis or secondary prevention where appropriate), define monitoring and stopping rules, and outline how to adjust immunosuppression while managing cytopenias and renal dysfunction, highlighting evidence gaps.